Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia.

Kutszegi N, Yang X, Gézsi A, Schermann G, Erdélyi DJ, Semsei ÁF, Gábor KM, Sági JC, Kovács GT, Falus A, Zhang H, Szalai C.

Haematologica. 2017 Sep;102(9):1578-1586. doi: 10.3324/haematol.2017.168211. Epub 2017 Jun 8.

2.

Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.

Farkas T, Müller J, Erdelyi DJ, Csoka M, Kovacs GT.

Pathol Oncol Res. 2017 Oct;23(4):889-897. doi: 10.1007/s12253-017-0192-8. Epub 2017 Jan 30.

PMID:
28138921
3.

[Extracellular vesicles and their role in hematological malignancies].

Rzepiel A, Kutszegi N, Cs Sági J, Kelemen A, Pálóczi K, F Semsei Á, Buzás E, Erdélyi DJ.

Orv Hetil. 2016 Aug;157(35):1379-84. doi: 10.1556/650.2016.30532. Review. Hungarian.

PMID:
27569460
4.

Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.

Hegyi M, Arany A, Semsei AF, Csordas K, Eipel O, Gezsi A, Kutszegi N, Csoka M, Muller J, Erdelyi DJ, Antal P, Szalai C, Kovacs GT.

Oncotarget. 2017 Feb 7;8(6):9388-9398. doi: 10.18632/oncotarget.11543.

5.

Pharmacogenetics of anthracyclines.

Sági JC, Kutszegi N, Kelemen A, Fodor LE, Gézsi A, Kovács GT, Erdélyi DJ, Szalai C, Semsei ÁF.

Pharmacogenomics. 2016 Jun;17(9):1075-87. doi: 10.2217/pgs-2016-0036. Epub 2016 Jun 8. Review.

PMID:
27266419
6.

Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.

Kutszegi N, Semsei ÁF, Gézsi A, Sági JC, Nagy V, Csordás K, Jakab Z, Lautner-Csorba O, Gábor KM, Kovács GT, Erdélyi DJ, Szalai C.

PLoS One. 2015 Oct 12;10(10):e0140136. doi: 10.1371/journal.pone.0140136. eCollection 2015.

7.

Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project.

Stark D, Bielack S, Brugieres L, Dirksen U, Duarte X, Dunn S, Erdelyi DJ, Grew T, Hjorth L, Jazbec J, Kabickova E, Konsoulova A, Kowalczyk JR, Lassaletta A, Laurence V, Lewis I, Monrabal A, Morgan S, Mountzios G, Olsen PR, Renard M, Saeter G, van der Graaf WT, Ferrari A.

Eur J Cancer Care (Engl). 2016 May;25(3):419-27. doi: 10.1111/ecc.12365. Epub 2015 Aug 4.

PMID:
26239724
8.

Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.

Gabor KM, Schermann G, Lautner-Csorba O, Rarosi F, Erdelyi DJ, Endreffy E, Berek K, Bartyik K, Bereczki C, Szalai C, Semsei AF.

Pediatr Blood Cancer. 2015 Apr;62(4):622-8. doi: 10.1002/pbc.25379. Epub 2015 Jan 3.

PMID:
25557962
9.

In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia.

Gézsi A, Lautner-Csorba O, Erdélyi DJ, Hullám G, Antal P, Semsei ÁF, Kutszegi N, Hegyi M, Csordás K, Kovács G, Szalai C.

Pharmacogenomics J. 2015 Jun;15(3):241-7. doi: 10.1038/tpj.2014.60. Epub 2014 Sep 30.

PMID:
25266680
10.

Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.

Csordas K, Lautner-Csorba O, Semsei AF, Harnos A, Hegyi M, Erdelyi DJ, Eipel OT, Szalai C, Kovacs GT.

Br J Haematol. 2014 Aug;166(3):410-20. doi: 10.1111/bjh.12886. Epub 2014 Apr 9.

PMID:
24712521
11.

Roles of genetic polymorphisms in the folate pathway in childhood acute lymphoblastic leukemia evaluated by Bayesian relevance and effect size analysis.

Lautner-Csorba O, Gézsi A, Erdélyi DJ, Hullám G, Antal P, Semsei ÁF, Kutszegi N, Kovács G, Falus A, Szalai C.

PLoS One. 2013 Aug 5;8(8):e69843. doi: 10.1371/journal.pone.0069843. Print 2013.

12.

The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy.

Eipel OT, Németh K, Török D, Csordás K, Hegyi M, Ponyi A, Ferenczy A, Erdélyi DJ, Csóka M, Kovács GT.

Int J Hematol. 2013 Feb;97(2):216-22. doi: 10.1007/s12185-012-1236-1. Epub 2013 Jan 26.

PMID:
23355259
13.

Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.

Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs GT.

Anticancer Drugs. 2013 Feb;24(2):189-97. doi: 10.1097/CAD.0b013e32835b8662.

PMID:
23187460
14.

Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance.

Lautner-Csorba O, Gézsi A, Semsei AF, Antal P, Erdélyi DJ, Schermann G, Kutszegi N, Csordás K, Hegyi M, Kovács G, Falus A, Szalai C.

BMC Med Genomics. 2012 Sep 28;5:42. doi: 10.1186/1755-8794-5-42.

15.

Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.

Hegyi M, Gulácsi A, Cságoly E, Csordás K, Eipel OT, Erdélyi DJ, Müller J, Nemes K, Lautner-Csorba O, Kovács GT.

J Cancer Res Clin Oncol. 2012 Oct;138(10):1697-702. Epub 2012 Jun 1.

PMID:
22652833
16.

ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia.

Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS, Lautner-Csorba O, Szabolcs J, Masat P, Fekete G, Falus A, Szalai C, Kovacs GT.

Cell Biol Int. 2012 Jan;36(1):79-86. doi: 10.1042/CBI20110264.

PMID:
21929509
17.

Urine catecholamines in paediatrics.

Erdelyi DJ, Elliott M, Phillips B.

Arch Dis Child Educ Pract Ed. 2011 Jun;96(3):107-11. doi: 10.1136/adc.2010.207126. No abstract available.

PMID:
21566154
18.

Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.

Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Gonzalez Neira A, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS.

Nat Genet. 2010 Jun;42(6):492-4. doi: 10.1038/ng.585. Epub 2010 May 9.

19.

Late immune recovery in children treated for malignant diseases.

Kovacs GT, Barany O, Schlick B, Csoka M, Gado J, Ponyi A, Müller J, Nemeth J, Hauser P, Erdelyi DJ.

Pathol Oncol Res. 2008 Dec;14(4):391-7. doi: 10.1007/s12253-008-9073-5. Epub 2008 Jun 25.

PMID:
18575827
20.

Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.

Semsei AF, Erdélyi DJ, Ungvári I, Kámory E, Csókay B, Andrikovics H, Tordai A, Cságoly E, Falus A, Kovács GT, Szalai C.

Leuk Res. 2008 Aug;32(8):1214-20. doi: 10.1016/j.leukres.2007.12.009. Epub 2008 Feb 19.

PMID:
18243305
21.

The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia.

Erdélyi DJ, Kámory E, Zalka A, Semsei AF, Csókay B, Andrikovics H, Tordai A, Borgulya G, Magyarosy E, Galántai I, Fekete G, Falus A, Szalai C, Kovács GT.

Cell Immunol. 2006 Dec;244(2):121-4. Epub 2007 Apr 16.

PMID:
17434155

Supplemental Content

Loading ...
Support Center